These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
259 related articles for article (PubMed ID: 36800625)
1. Diagnosis, treatment, and genetic characteristics of blastic plasmacytoid dendritic cell neoplasm: A review. Wang Y; Xiao L; Yin L; Zhou L; Deng Y; Deng H Medicine (Baltimore); 2023 Feb; 102(7):e32904. PubMed ID: 36800625 [TBL] [Abstract][Full Text] [Related]
2. Diagnostic management of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in close interaction with therapeutic considerations. Shumilov E; Mazzeo P; Ghandili S; Künstner A; Weidemann S; Banz Y; Ströbel P; Pollak M; Kolloch L; Beltraminelli H; Kerkhoff A; Mikesch JH; Schliemann C; Haase D; Wulf G; Legros M; Lenz G; Feldmeyer L; Pabst T; Witte H; Gebauer N; Bacher U Ann Hematol; 2024 May; 103(5):1587-1599. PubMed ID: 38194088 [TBL] [Abstract][Full Text] [Related]
6. New perspectives in genetics and targeted therapy for blastic plasmacytoid dendritic cell neoplasm. Zhang X; Sun J; Yang M; Wang L; Jin J Crit Rev Oncol Hematol; 2020 May; 149():102928. PubMed ID: 32234682 [TBL] [Abstract][Full Text] [Related]
7. Blastic plasmacytoid dendritic cell neoplasm: update on molecular biology, diagnosis, and therapy. Riaz W; Zhang L; Horna P; Sokol L Cancer Control; 2014 Oct; 21(4):279-89. PubMed ID: 25310209 [TBL] [Abstract][Full Text] [Related]
8. Pediatric blastic plasmacytoid dendritic cell neoplasm: report of four cases and review of literature. Liao C; Hu NX; Song H; Zhang JY; Shen DY; Xu XJ; Tang YM Int J Hematol; 2021 May; 113(5):751-759. PubMed ID: 33392975 [TBL] [Abstract][Full Text] [Related]
9. A critical review of treatment modalities for blastic plasmacytoid dendritic cell neoplasm. Falcone U; Sibai H; Deotare U Crit Rev Oncol Hematol; 2016 Nov; 107():156-162. PubMed ID: 27823644 [TBL] [Abstract][Full Text] [Related]
10. Recent Advances in the Biology and CD123-Directed Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm. Pemmaraju N; Deconinck E; Mehta P; Walker I; Herling M; Garnache-Ottou F; Gabarin N; Campbell CJV; Duell J; Moshe Y; Mughal T; Mohty M; Angelucci E Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):e130-e137. PubMed ID: 38267355 [TBL] [Abstract][Full Text] [Related]
11. Blastic Plasmacytoid Dendritic Cell Neoplasm: From Origin of the Cell to Targeted Therapies. Laribi K; Denizon N; Besançon A; Farhi J; Lemaire P; Sandrini J; Truong C; Ghnaya H; Baugier de Materre A Biol Blood Marrow Transplant; 2016 Aug; 22(8):1357-1367. PubMed ID: 27026248 [TBL] [Abstract][Full Text] [Related]
12. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): A promising future in the era of targeted therapeutics. Adimora IJ; Wilson NR; Pemmaraju N Cancer; 2022 Aug; 128(16):3019-3026. PubMed ID: 35726525 [TBL] [Abstract][Full Text] [Related]
13. Novel Therapeutic Approaches in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Era of Targeted Therapy. Wilson NR; Konopleva M; Khoury JD; Pemmaraju N Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):734-740. PubMed ID: 34226167 [TBL] [Abstract][Full Text] [Related]
14. Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark. Taylor J; Haddadin M; Upadhyay VA; Grussie E; Mehta-Shah N; Brunner AM; Louissaint A; Lovitch SB; Dogan A; Fathi AT; Stone RM; Tallman MS; Rampal RK; Neuberg DS; Stevenson KE; Horwitz SM; Lane AA Blood; 2019 Aug; 134(8):678-687. PubMed ID: 31243042 [TBL] [Abstract][Full Text] [Related]
15. Blastic plasmacytoid dendritic cell neoplasm: emerging developments and special considerations for 2023. Pemmaraju N; Kantarjian H Clin Adv Hematol Oncol; 2023 May; 21(5):257-264. PubMed ID: 37145496 [TBL] [Abstract][Full Text] [Related]
16. Blastic plasmacytoid dendritic cell neoplasm: update on therapy especially novel agents. Wang S; Wang X; Liu M; Bai O Ann Hematol; 2018 Apr; 97(4):563-572. PubMed ID: 29455234 [TBL] [Abstract][Full Text] [Related]
19. Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations. Pemmaraju N; Madanat YF; Rizzieri D; Fazal S; Rampal R; Mannis G; Wang ES; Foran J; Lane AA Leuk Lymphoma; 2024 May; 65(5):548-559. PubMed ID: 38391126 [TBL] [Abstract][Full Text] [Related]
20. A blastic plasmacytoid dendritic cell neoplasm-like immunophenotype is negatively associated with CEBPA bZIP mutation and predicts unfavorable prognosis in acute myeloid leukemia. Song J; Li W; Bai Y; Zhou P; Niu J; Niu X; Liu Y; Liu X; Drokow EK; Sun K; Zhou H Ann Hematol; 2024 Feb; 103(2):463-473. PubMed ID: 38183444 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]